Y 688
Latest Information Update: 13 May 1998
Price :
$50 *
At a glance
- Originator Mitsubishi Pharma Corporation
- Class Antibacterials; Fluoroquinolones
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections